Method for preparing AIDS immunoadsorption therapeutic cell line

Abstract

The invention discloses a method for preparing an AIDS immunoadsorption therapeutic cell line in the biomedical field. The method is characterized in that CD4+T cells and macrophages are sorted by animmunomagnetic bead method and are placed in a pre-fusion agent containing PHA, concanavalin A, IFN-gamma, SP2 / 0-IgG and CD4-IgG with myeloma cells (SP2 / 0), under combined action of PHA-activated T cells, concanavalin A for change of cell membrane solubility and an IFN-gamma activated macrophage IgGFc receptor, the IgGFab segment of CD4-IgG is bonded to CD4+T cells having CD4 epitope, the IgGFc segment is bonded to macrophages with IgGFc receptors, the IgGFab segment of SP2 / 0-IgG is bonded to the SP2 / 0 and the IgGFc segment is bonded to macrophages with IgGFc receptors so that a CD4+T cell-CD4-IgG-macrophage-IgG-SP2 / 0 conjugate is formed, three types of cells are fused under the action of a fusion agent, and the fused cells are cultured by a cell fusion selection medium (HAT) so that the AIDS immunoadsorption therapeutic cell line with effects of long-term passage, production of cytokines and HIV endocytosis is acquired.

Description

technical field [0001] The invention relates to biological cell therapy of AIDS in the field of biomedicine. Background technique [0002] AIDS is an infectious disease caused by human immunodeficiency virus (Human Immunodeficiency Virus, HIV). So far, 208 countries and regions in the world have been seriously threatened by AIDS. About 40 million people have been infected with AIDS, and the death toll has exceeded 20 million. About 6,000 people become AIDS-infected people every day, and more than 300 people die every day. on AIDS. HIV-infected people in China are in a period of rapid growth, and the number has far exceeded 1 million at present. AIDS has become another major infectious disease facing mankind after tumors, cardiovascular and cerebrovascular diseases, tuberculosis, and diabetes, and has become a serious public health and social problem of global concern. [0003] Judging from the current AIDS treatment methods that have been used clinically, the effect is no...

AI Technical Summary

Problems solved by technology

[0003] Judging from the current AIDS treatment methods that have been used clinically, the effect is not so ideal: (1) HIV reverse transcriptase inhibitors: can only prevent the infection of susceptible cells that have not been infected with HIV, and have no therapeutic effect on infected cells, and are toxic There are many side effects, including mitochondrial toxicity, myelosuppression, erythrocytic anemia, neutropenia and thrombocytopenia, pancreatitis, and the generation of cross-drug resistance. Drug-resistant variants, resulting in decreased clinical efficacy or failure

(2) HIV protease inhibitors: prone to drug-induced liver injury, lipid metabolism disorders and other side effects and drug resistance

(4) Inhibiting HIV virus entry inhibitors: including blocking the binding of gp120 to CD4, blocking the binding of HIV to coreceptors, acting on gp41 membrane subunits, and acting on CC chemokine receptor 5 (CCR5) on the surface of T lymphocytes to block HIV from entering host cells, but has side effects on the liver and heart

(6) HIV vaccine treatment: Due to the particularity of HIV, such as innate immunity is not enough to resist HIV and its targeted destruction of the immune system, and the virus mutates rapidly, so far no truly safe and effective vaccine has been developed

(7) Gene therapy: HIV gene therapy research has never stopped, including antisense technology, RNA decoy, RNA interference, intracellular antibodies, dominant negative mutants, suicide genes, etc., but gene therapy that has entered phase II clinical trials hardly

(8) Monoclonal antibody passive immunotherapy: reduce the susceptibility of HIV, delay the progression of AIDS and reduce the spread of HIV by down-regulating CCR5 on the surface of CD4+ T cells. Neutralizing monoclonal antibodies 2G12, 2F5 and 4E10 are applied to HIV-infected patients It has good tolerance and safety, and can delay but not prevent the rebound of the virus (9) Adoptive immune cell therapy: when a large number of HIV autologous CD4+ T cells are cultured in vitro, it will lead to a large amount of virus amplification and increase the CD4+ T cells infected by the virus. +T cell number, and reinfusion of CD4+T cells may increase the place where the virus replicates in the body, resulting in a rebound of the viral load. Generally speaking, adoptive immune cell therapy has no obvious side effects and has not achieved satisfactory therapeutic effect

Images